BIA responds to MHRA update on Brexit preparations

Press release for immediate release:

Tuesday 16th January 2018

 

The BIA has today responded to an update from the Medicines and Healthcare products Regulatory Agency (MHRA) to pharmaceutical companies on preparations for exiting the European Union.

Responding to today’s publication of the MHRA statement BIA Head of Regulatory Affairs, Dr Christiane Abouzeid, said:

“The MHRA update to biotech/pharmaceutical companies on Brexit preparations is welcome and provides public clarity on the UK’s current regulatory relationship with the European medicines network of Member States and the European Medicines Agency (EMA), and their planned pragmatic approach in establishing UK regulatory requirements for the eventuality of a no deal scenario and no relationship with the network.

The BIA has long advocated for retaining ongoing UK regulatory cooperation with the European Union on medicines to ensure minimal disruption to patient access in both the UK and EU. This is also the UK government’s preferred outcome. We continue to work closely with the UK government, the MHRA and partner organisations across the EU 27 Member States towards that goal.”

Ends

Notes to Editors

Contact: Ed Sexton, BIA Communications and Media Relations Manager: esexton@bioindustry.org  or call 0207 630 2196

About the UK BioIndustry Association (BIA)

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

More within